Is bivi a good buy

**BioVie Inc. (BIVI)** does not appear to be a good buy at this time based on several financial and technical indicators: 1. **Financial Performance**: - BIVI reported a net income of -$8.07 million and a diluted EPS of -$0.20 for the most recent quarter. - The company's net income has decreased by 46.36%, and its total revenue has decreased by 9.09%. 2. **Growth Prospects**: - BIVI has received all necessary scientific approvals for an additional $12.6 million in grant funding from the U.S. Department of Defense to initiate a planned Phase 2 trial of bezisterim focused on long COVID. - The company has a history of insider selling, which could indicate a lack of confidence from those closest to the company. 3. **Market Position and Competitive Landscape**: - BIVI operates in the biopharmaceutical industry, focusing on treatments for liver disease and neurological disorders. - The company faces competition from established pharmaceutical companies and must differentiate its treatments to succeed. 4. **Recent Developments**: - BIVI has undergone a reverse stock split, which may have helped to improve its stock's marketability, but does not address the underlying financial challenges. - The company has announced a public offering to raise approximately $3 million, which could be used for working capital and general corporate purposes. 5. **Insider Activity and Institutional Interest**: - There has been a significant drop in short interest, which could indicate improving investor sentiment. - Institutional ownership of BIVI has decreased, with a 94% drop in short interest. In conclusion, while BIVI has strategic partnerships and a promising pipeline, the current financial and technical indicators suggest caution. The company's net loss, decline in revenue, and history of insider selling raise concerns about its financial stability and the sustainability of its business model. Investors should carefully consider these factors before making an investment decision.